These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38378248)

  • 41. TAFRO syndrome is associated with anti-SSA/Ro60 antibodies, in contrast to idiopathic castleman disease.
    Shirakashi M; Nishida Y; Nakashima R; Fujimoto M; Hiwa R; Tsuji H; Kitagori K; Akizuki S; Morinobu A; Yoshifuji H
    Sci Rep; 2024 Feb; 14(1):2889. PubMed ID: 38311632
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series.
    Lust H; Gong S; Remiker A; Rossoff J
    Pediatr Blood Cancer; 2021 Oct; 68(10):e29261. PubMed ID: 34302703
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunohistochemical analysis of IgA expression differentiates IgG4-related disease from plasma cell-type Castleman disease.
    Manabe A; Igawa T; Takeuchi M; Gion Y; Yoshino T; Sato Y
    Med Mol Morphol; 2017 Mar; 50(1):34-41. PubMed ID: 27438709
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of IgG4-Related Lymphadenopathy and Multicentric Castleman's Disease: a Retrospective Study.
    Sun C; Xu G; Lin J
    Clin Lab; 2018 Oct; 64(10):1671-1678. PubMed ID: 30336525
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease.
    Fajgenbaum DC; Langan RA; Japp AS; Partridge HL; Pierson SK; Singh A; Arenas DJ; Ruth JR; Nabel CS; Stone K; Okumura M; Schwarer A; Jose FF; Hamerschlak N; Wertheim GB; Jordan MB; Cohen AD; Krymskaya V; Rubenstein A; Betts MR; Kambayashi T; van Rhee F; Uldrick TS
    J Clin Invest; 2019 Aug; 129(10):4451-4463. PubMed ID: 31408438
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Elevated serum interferon γ-induced protein 10 kDa is associated with TAFRO syndrome.
    Iwaki N; Gion Y; Kondo E; Kawano M; Masunari T; Moro H; Nikkuni K; Takai K; Hagihara M; Hashimoto Y; Yokota K; Okamoto M; Nakao S; Yoshino T; Sato Y
    Sci Rep; 2017 Feb; 7():42316. PubMed ID: 28205564
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The histological diagnosis of IgG4-related disease on small biopsies: challenges and pitfalls.
    Arora K; Rivera M; Ting DT; Deshpande V
    Histopathology; 2019 Apr; 74(5):688-698. PubMed ID: 30408214
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Recent advances in diagnosis and treatment of idiopathic multicentric Castleman disease].
    Okamoto S
    Rinsho Ketsueki; 2019; 60(9):1205-1211. PubMed ID: 31597845
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Castleman disease and TAFRO syndrome: To improve the diagnostic consciousness is the key.
    Zhou QY
    World J Clin Cases; 2022 Feb; 10(5):1536-1547. PubMed ID: 35211591
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Increase in Vascular Endothelial Growth Factor (VEGF) Expression and the Pathogenesis of iMCD-TAFRO.
    Srkalovic G; Nijim S; Srkalovic MB; Fajgenbaum D
    Biomedicines; 2024 Jun; 12(6):. PubMed ID: 38927535
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report.
    Lang E; Sande B; Brodkin S; van Rhee F
    Ther Adv Hematol; 2022; 13():20406207221082552. PubMed ID: 35251585
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetic basis for iMCD-TAFRO.
    Yoshimi A; Trippett TM; Zhang N; Chen X; Penson AV; Arcila ME; Pichardo J; Baik J; Sigler A; Harada H; Fajgenbaum DC; Dogan A; Abdel-Wahab O; Xiao W
    Oncogene; 2020 Apr; 39(15):3218-3225. PubMed ID: 32051554
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study.
    Yu L; Shi M; Cai Q; Strati P; Hagemeister F; Zhai Q; Li L; Fang X; Li J; Sun R; Zhang S; Yang H; Wang Z; Qian W; Iwaki N; Sato Y; Zhang L; Li J; Oksenhendler E; Xu-Monette ZY; Young KH
    Oncologist; 2020 Nov; 25(11):963-973. PubMed ID: 32852137
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Pathological significance of plasma cell infiltration in diagnosing lymph node diseases].
    Hu H; Jiang YJ; Xu L; Yin LJ; Liu XF; Yin SY; Xu JJ; He MX
    Zhonghua Bing Li Xue Za Zhi; 2023 Jul; 52(7):702-709. PubMed ID: 37408401
    [No Abstract]   [Full Text] [Related]  

  • 55. Multicentric Castleman Disease With Tubulointerstitial Nephritis Mimicking IgG4-related Disease: Two Case Reports.
    Zoshima T; Yamada K; Hara S; Mizushima I; Yamagishi M; Harada K; Sato Y; Kawano M
    Am J Surg Pathol; 2016 Apr; 40(4):495-501. PubMed ID: 26598921
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Castleman disease, TAFRO syndrome, idiopathic plasmacytic lymphadenopathy, and autoimmune disease.
    Nakamura N
    J Clin Exp Hematop; 2022; 62(2):58-59. PubMed ID: 35768239
    [No Abstract]   [Full Text] [Related]  

  • 57. Long-Term Tolerance and Efficacy of Siltuximab (Anti-IL-6) in a Young Adult with Idiopathic Multicentric Castleman Disease During COVID-19.
    Bedier H; Isnard S; Maedler-Kron C; Routy JP
    Eur J Case Rep Intern Med; 2023; 10(12):004098. PubMed ID: 38077710
    [TBL] [Abstract][Full Text] [Related]  

  • 58. T-Cells Subsets in Castleman Disease: Analysis of 28 Cases Including Unicentric, Multicentric and HHV8-Related Clinical Forms.
    Fraticelli S; Lucioni M; Neri G; Marchiori D; Cristinelli C; Merli M; Monaco R; Borra T; Lazzaro A; Uccella S; Arcaini L; Paulli M
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175521
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease.
    Iwaki N; Fajgenbaum DC; Nabel CS; Gion Y; Kondo E; Kawano M; Masunari T; Yoshida I; Moro H; Nikkuni K; Takai K; Matsue K; Kurosawa M; Hagihara M; Saito A; Okamoto M; Yokota K; Hiraiwa S; Nakamura N; Nakao S; Yoshino T; Sato Y
    Am J Hematol; 2016 Feb; 91(2):220-6. PubMed ID: 26805758
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Diagnostic dilemma of IgG4-related primary localized cervical lymphadenopathy associated with aberrant IL-6 expression level.
    Nakamura M; Iwamoto O; Chino T; Todoroki K; Kusukawa J
    Diagn Pathol; 2016 May; 11(1):43. PubMed ID: 27142509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.